About GSK
GSK is a Healthcare company based in Vancouver (Canada) founded in 2003, and was acquired by GSK in April 2022. GSK is engaged in developing biopharmaceutical solutions globally. It operates on a Direct-to-Consumer (D2C) and Professional Services model. GSK has raised $74.98 million across 3 funding rounds from investors including Orbimed, Janus Henderson Investors and RA Capital. GSK offers products and services including Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions. Its focus areas include Pharmaceuticals and Biopharmaceuticals. Its legal entity is GSK plc.
Company details
GSK, a leading biopharmaceutical company, is focused on uniting science, technology, and talent to address diseases. Operations are centered in therapeutic areas such as respiratory, immunology, inflammation, oncology, HIV, and infectious diseases. Solutions are developed to improve global health access, particularly in lower-income regions. Commitment is shown towards environmental sustainability and ethical standards. Research and development efforts are prioritized to impact 2.5 billion people by the decades end. Partnerships and strategic programs are utilized to enhance healthcare delivery across diverse markets.
Products & Services of GSK
GSK offers a comprehensive portfolio of products and services, including Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions.
Solutions for respiratory conditions are developed and provided.
Cancer treatments are researched and offered for patients.
HIV therapies are created to manage the condition.
Treatments for infectious diseases are developed and distributed.
Apps and channels of GSK
its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.
Videos from GSK
The most watched videos on GSK's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.
More on ViiV Healthcare.
Funding Insights of GSK
GSK has successfully raised a total of $74.98M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $59.5 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $74.98M
- Total Rounds 3
- Last Round Series D β $59.5M
- First Round $4.3M
(Jun 2013)
- Investors Count 13
All 3 funding rounds of GSK with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | $59.5M | Series D | β | Vivo Capital | |
| Dec 2013 | $11.18M | Series B | β | β | β |
| Jun 2013 | $4.3M | Series A | β | β | β |
14 investors in total: 14 institutional.
Investors in GSK
GSK has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
| hopenls.com | ||||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
| capitalmidwest.com | ||||
A venture capital firm focused on life sciences investments. | 2005 | apjohnventures.com | Kalamazoo, United States | |
Venture capital and private equity investments are managed by Amherst Fund. | 2003 | amherstfund.com | Ann Arbor, USA |
Investor details for GSK
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GSK
962 people are tracked at GSK (578 in leadership, 9 in board & advisors, 375 in team).
| Name | Role | Group |
|---|---|---|
Enoch Acquah | Production Value Stream Director | Leadership |
Rosirene Paczkowski | Director | Leadership |
Avijit Ray | Director | Leadership |
John Hong | Medicine Supply Chain Leader (director) | Leadership |
Angela Avila | Finance Director | Leadership |
Sarit Cohen-Rabbie | Clinical Development Director, Immunology | Leadership |
Renata Scofield | Global Senior Director, Environmental Stewardship | Leadership |
David Redfern | President, Corporate Development | Leadership |
Jiaying Ji | Head Of China Talent Acquisition | Leadership |
Sean Evans | Director, Strategic Alliances | Leadership |
Sergio Serrano Caballero | Digital Business Partner | Leadership |
Heidi Feldser | Scientific Director | Leadership |
Kyle Robinson | Associate Director External Operations | Leadership |
Christophe Lambert | Head Of Viral Computational Genomics | Leadership |
Rajesh Gurumurthy | Director Strategic Procurement (senior Principal Product Owner) Global Products & Technology | Leadership |
Victoria Sanchez Zini | Director R&d Strategy - RD Strategy & Portfolio Management / Office Of The CSO | Leadership |
Cristelle Noirhomme | Head Of Belgium Corporate Government Affairs | Leadership |
Yogitaa Gahlot Saha | Director - Finance | Leadership |
Raye Yohannes Melka | Associate Director Downstream Process Development | Leadership |
Andrea Haynes | Senior Scientific Director, Head Of Experimental Quantitative Pharmacology | Leadership |
942 more people are available in the full profile.
Complete people profiles for GSK
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GSK
5 dated milestones of GSK across 19 years, from founding to its latest funding, stage changes and deals.
- Founded GSK is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Series D, of $59.5M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by GSK.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gsk
Complete news archive for GSK
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GSK
GSK was founded in 2003 and raised its 1st funding round 10 years after it was founded.
GSK is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
GSK is a funded company, having raised a total of $74.98M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.3M, raised on Jun 2013.
GSK, a leading biopharmaceutical company, is focused on uniting science, technology, and talent to address diseases. Operations are centered in therapeutic areas such as respiratory, immunology, inflammation, oncology, HIV, and infectious diseases. Solutions are developed to improve global health access, particularly in lower-income regions. Commitment is shown towards environmental sustainability and ethical standards. Research and development efforts are prioritized to impact 2.5 billion people by the decades end. Partnerships and strategic programs are utilized to enhance healthcare delivery across diverse markets.
GSK offers Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions.
GSK has 14 investors. Key investors include Orbimed, Janus Henderson Investors, RA Capital, Frazier Healthcare Partners, and GSK.
GSK operates through Gsk Plc.
Yes. GSK was acquired by GSK in April 2022.

